Current Report Filing (8-k)
June 02 2020 - 04:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 2, 2020
_______________________________
Citius Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter)
_______________________________
Nevada
(State or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
11 Commerce Drive, 1st Floor, Cranford, NJ
|
|
07016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area
code (908) 967-6677
_______________________________
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.001 par value
|
|
CTXR
|
|
The Nasdaq Capital Market
|
Warrants to purchase common stock
|
|
CTXRW
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 8.01.
|
Other Material Information.
|
On June 2, 2020, Citius Pharmaceuticals, Inc. issued a
press release to announce that it had received positive feedback from the FDA on its submitted plan to study catheter compatibility
for its Mino-Lok® therapy. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 2, 2020
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
|
/s/ Myron Holubiak
|
|
Myron Holubiak
President and Chief Executive Officer
|
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Mar 2023 to Mar 2024